BioMarin Pharmaceutical Inc. priced its latest rare disease drug Tuesday at $380,000 a year. But the most interesting thing about the price of Vimizim, the San Rafael-based drug developer’s recently approved enzyme replacement therapy for people with Morquio A syndrome, is that BioMarin isn’t even close to being No. 1. In fact, Vimizim would have to raise its price by more than $35,000 even to reach second place.
Hey, check out all the research scientist jobs. Post your resume today!
